Semaglutide was the most commonly used GLP ... It can progress quickly and is a leading cause of vision loss in adults over 60. While there are treatments to slow the disease, early detection ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

The European Medicines Agency (EMA) has warned that popular weight-loss and diabetes drugs containing semaglutide — including ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

Plastic surgeon Dr Benjamin Wabwire explains the current landscape of clinical weight management and why deeper scrutiny is ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

A European health authority has found that medications containing semaglutide—such as Ozempic, Wegovy, and Rybelsus—can ...

Semaglutide, widely used to treat diabetes ... irreversible central vision loss due to abnormal blood vessel growth that damages the macula. Warnings first surfaced from major diabetes trials ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...